Rare - RARE

Short interest for Ultragenyx Pharmaceutical gives investors a sense of the degree to which investors are betting on the decline of Ultragenyx Pharmaceutical's stock. Short interest data is updated every two weeks.

Ultragenyx Pharmaceutical Stock (NASDAQ:RARE), Short Interest Report

Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Earnings

News

Penny Stocks

Eurozone

Commodities

Small Cap

Global

Intraday Update

Markets

Trading Ideas

LGVN

MRNS

NMRA

RARE

SNGX

SNPO

U.S. stocks turned lower toward the end of trading, with the S&amp;P 500 falling more than 1% on Monday.

The Dow traded down 0.64% to 37,741.18 while the NASDAQ fell 1.68% to 15,902.96. The S&amp;P 500 also fell, dropping, 1.14% to 5,065.04.

S&amp;P 500 Down Over 1%; US Retail Sales Increase 0.7% In March

Movers

ADIL

AEYE

Alterity Therapeutics Limited - American Depositary Shares

ATHE

BHVN

BTCY

CENX

CMAX

Envoy Medical, Inc. - Class A Common Stock

COCH

DXYZ

EGIO

EXTR

HUBC

IMCC

INFA

KAVL

KUKE

LOCL

MNDR

Nuveen California Dividend Advantage Municipal Fund 2

NXPL

ONVO

PROK

PSNY

QTTB

RENT

SPCB

SPWR

SRFM

SWVL

TCON

VERU

VIAO

WIRE

Shares of  Ultragenyx Pharmaceutical Inc.  (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

SCHW

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Monday.

The Dow traded up 0.35% to 38,114.61 while the NASDAQ rose 0.07% to 16,187.02. The S&amp;P 500 also rose, gaining, 0.26% to 5,136.94.

Crude Oil Down 1%; Charles Schwab Sales Top Estimates

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical Inc

SuperRare - United States Dollar

CANADA RARE EARTH CP ORD by Canada Rare Earth Corp.

Canada Rare Earth Corp

RARE ELEMENT RES LTD by Rare Element Resources Ltd.

Rare Element Resources Ltd

RareX Ltd

Rareview Dynamic Fixed Income ETF

Rareview Tax Advantaged Income ETF

Cantor Fitzgerald analyst Kristen Kluska reiterates Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) with a Overweight and maintains $107 price target.

Price Target

Reiteration

Analyst Ratings

Cantor Fitzgerald Reiterates Overweight on Ultragenyx Pharmaceutical, Maintains $107 Price Target

Wedbush analyst Laura Chico maintains Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) with a Neutral and lowers the price target from $48 to $47.

Wedbush Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $47

General

Ultragenyx Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q1 financial results.

WIIM

Guidance

Ultragenyx Pharmaceutical Sees FY24 Revenue $500M-$530M Vs $513M Est.

Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) reported quarterly losses of $(2.03) per share which missed the analyst consensus estimate of $(1.77) by 14.69 percent. The company reported quarterly sales of $108.833 million which missed the analyst consensus estimate of $116.009 million by 6.19 percent. This is a 8.30 percent increase over sales of $100.496 million the same period last year.

Earnings Misses

Ultragenyx Pharmaceutical Q1 2024 GAAP EPS $(2.03) Misses $(1.77) Estimate, Sales $108.833M Miss $116.009M Estimate

Ultragenyx Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) today announced that all patients have been enrolled across the Phase 3 Orbit and Cosmic studies evaluating setrusumab (UX143) in pediatric and young adult patients with osteogenesis imperfecta (OI). The pivotal Phase 3 portion of the Orbit study has randomized 158 patients ages 5 to 25 years, and the Cosmic study has completed enrollment of 66 patients ages 2 to &lt;7 years. &nbsp;
"We would like to thank the OI community for its support, trust and participation as we complete this important step in the advancement of the setrusumab program," said Eric Crombez, M.D., chief medical officer at Ultragenyx. "The interim Phase 2 Orbit study results show a rapid and clinically meaningful decrease in fracture rate, giving us confidence in our ability to bring this potential new treatment to patients living with OI. Our goal is to provide patients and their families a novel treatment that can significantly reduce the burden of fractures and improve their quality of life by building new and stronger bone."
"From a clinical perspective the important thing is that we are potentially closer to the goal of having a treatment for children - including very young children - with osteogenesis imperfecta," stated Nick Bishop, Professor of Paediatric Bone Disease at University of Sheffield Medical School. "The interim Phase 2 results are very encouraging, and the speed with which we have been able to complete recruitment into both the Orbit and Cosmic studies clearly reflects the positive views of the study clinicians as a whole regarding this investigational therapy."
Data presented at the American Society for Bone and Mineral Research 2023 Annual Meeting (ASBMR) from the Phase 2 portion of the Orbit study showed that treatment with setrusumab reduced the median annualized fracture rate by 67% and this reduction was associated with continuing large and meaningful improvements in bone mineral density (BMD). Setrusumab was generally well tolerated with no drug-related serious adverse events (SAEs) reported and no reports of drug-related hypersensitivity. Additional longer-term Phase 2 safety and efficacy data from the Orbit study are expected in the second half of 2024.

Biotech

Ultragenyx Announces Completion Of Enrollment In Phase 3 Orbit And Cosmic Studies Evaluating Setrusumab For The Treatment Of Osteogenesis Imperfecta

TD Cowen analyst Yaron Werber maintains Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) with a Buy and raises the price target from $59 to $61.

TD Cowen Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $61

Ratings for Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) were provided by 11 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $82.55, along with a high estimate of $114.00 and a low estimate of $48.00. This upward trend is evident, with the current average reflecting a 6.93% increase from the previous average price target of $77.20.
<img src="https://www.benzinga.com/files/images/story/2024/1713787253_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Ultragenyx Pharmaceutical among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$77.00</td>
<td>-</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$48.00</td>
<td>-</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$48.00</td>
<td>-</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$107.00</td>
<td>-</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Cory Kasimov</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$88.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$107.00</td>
<td>-</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$111.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$48.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$114.00</td>
<td>-</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$68.00</td>
<td>$57.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Ultragenyx Pharmaceutical. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ultragenyx Pharmaceutical compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Ultragenyx Pharmaceutical's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Ultragenyx Pharmaceutical's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RARE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ultragenyx Pharmaceutical analyst ratings.</a>
<h2>Delving into Ultragenyx Pharmaceutical's Background</h2>
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
<h3>Unraveling the Financial Story of Ultragenyx Pharmaceutical</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining Ultragenyx Pharmaceutical's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 23.27% as of 31 December, 2023, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -96.7%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Ultragenyx Pharmaceutical's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -80.22%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -9.03%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Ultragenyx Pharmaceutical's debt-to-equity ratio is below the industry average. With a ratio of 0.16, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 11 Analyst Projections For Ultragenyx Pharmaceutical

RBC Capital analyst Luca Issi initiates coverage on Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) with a Outperform rating and announces Price Target of $77.

Initiation

RBC Capital Initiates Coverage On Ultragenyx Pharmaceutical with Outperform Rating, Announces Price Target of $77

Wedbush analyst Laura Chico reiterates Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) with a Neutral and maintains $48 price target.

Wedbush Reiterates Neutral on Ultragenyx Pharmaceutical, Maintains $48 Price Target

U.S. stocks turned lower toward the end of trading, with the S&amp;P 500 falling more than 1% on Monday.
The Dow traded down 0.64% to 37,741.18 while the NASDAQ fell 1.68% to 15,902.96. The S&amp;P 500 also fell, dropping, 1.14% to 5,065.04.
Check This Out: <a href="https://www.benzinga.com/news/24/04/38218786/best-buy-box-and-2-other-stocks-insiders-are-selling"> Best Buy, Box And 2 Other Stocks Insiders Are Selling </a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Health care shares rose by 0.01% on Friday.
In trading on Friday, information technology shares fell by 1.8%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
U.S. retail sales increased 0.7% month-over-month in March following a revised 0.9% rise in February.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Soligenix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sngx#NASDAQ">SNGX</a>) shares shot up 34% to $0.5197 after the company announced that it was granted orphan drug designation to the active ingredient in MarVax for the prevention and post-exposure prophylaxis against MARV infection by the FDA.
Shares of Longeveron Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lgvn#NASDAQ">LGVN</a>) got a boost, surging 58% to $2.6750 following insider buys from multiple company executives.
Snap One Holdings Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snpo#NASDAQ">SNPO</a>) shares were also up, gaining 30% to $10.60 after the company announced that it will be acquired by Resideo Technologies.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Marinus Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrns#NASDAQ">MRNS</a>) shares dropped 81% to $1.4250 after the company provided an update on the Phase 3 RAISE trial and reported preliminary first-quarter financial results.
Shares of Neumora Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nmra#NASDAQ">NMRA</a>) were down 11% to $12.02 after the FDA placed a clinical hold on the company&#39;s Phase 1 NMRA-266 study.
Ultragenyx Pharmaceutical Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rare#NASDAQ">RARE</a>) was down, falling 10% to $42.73 after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.
Also Check This Out:<a href="https://www.benzinga.com/news/24/04/38246593/wall-streets-most-accurate-analysts-views-on-3-tech-stocks-with-over-4-dividend-yields"> Wall Street&#39;s Most Accurate Analysts&#39; Views On 3 Tech Stocks With Over 4% Dividend Yields </a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded down 0.6% to $85.17 while gold traded up 0.3% at $2,381.50.
Silver traded up 1.6% to $28.795 on Friday, while copper rose 2.3% to $4.3575.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares closed mostly higher today. The eurozone&rsquo;s STOXX 600 rose 0.13%, London&rsquo;s FTSE 100 fell 0.38% while Spain&rsquo;s IBEX 35 Index rose 0.01% The German DAX gained 0.54% French CAC 40 climbed 0.43% while Italy&rsquo;s FTSE MIB Index jumped 0.56%.
Industrial production in the eurozone increased by 0.8% month-over-month in February.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed mostly lower on Monday, with Japan&rsquo;s Nikkei 225 falling 0.74%, Hong Kong&rsquo;s Hang Seng Index dropping 0.72%, China&rsquo;s Shanghai Composite gaining 1.26% and India&rsquo;s S&amp;P BSE Sensex dipping 1.14%.
Indian merchandise trade deficit shrank to $15.6 billion in March versus a year-ago gap of $18.1 billion, while wholesale prices rose by 0.53% year-over-year in March versus a 0.20% gain in the prior month.
&nbsp;
<h3>Economics</h3>
&nbsp;
The NY Empire State Manufacturing Index climbed to -14.3 in April versus prior month&rsquo;s reading of -20.9.
Retail sales increased 0.7% month-over-month in March following a revised 0.9% rise in February.
The NAHB/Wells Fargo Housing Market Index in came in unchanged at 51.0 in April.
Total business inventories increased by 0.4% month-over-month in February, versus market expectations of a 0.3% rise.
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38248683/bitcoin-surpasses-66-000-core-emerges-as-top-gainer"> Bitcoin Surpasses $66,000; Core Emerges As Top Gainer </a>
&nbsp;

S&P 500 Down Over 1%; US Retail Sales Increase 0.7% In March

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rare#NASDAQ">RARE</a>) fell sharply during Monday&rsquo;s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.
Ultragenyx Pharmaceutical shares dipped 9.4% to $42.46 on Monday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Soligenix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sngx#NASDAQ">SNGX</a>) shares surged 71.5% to $0.6679 after the company announced that it was granted orphan drug designation to the active ingredient in MarVax for the prevention and post-exposure prophylaxis against MARV infection by the FDA.</li>
<li>Longeveron Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lgvn#NASDAQ">LGVN</a>) surged 54% to $2.6350 following insider buys from multiple company executives.</li>
<li>SuperCom Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/spcb#NASDAQ">SPCB</a>) shares gained 39.4% to $0.3849 after jumping around 18% on Friday.</li>
<li>Piedmont Lithium Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pll#NYSE">PLL</a>) shares gained 32.1% to $16.75 following a 5% decline on Friday.</li>
<li>Snap One Holdings Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snpo#NASDAQ">SNPO</a>) surged 31.6% to $10.71 after the company announced that it will be acquired by Resideo Technologies.</li>
<li>Organovo Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/onvo#NASDAQ">ONVO</a>) shares surged 30.9% to $1.32 after the company announced Phase 2 results for FXR314. Study results demonstrated statistically significant reduction in liver fat content from baseline in patients receiving FXR314 compared to placebo.</li>
<li>Kuke Music Holding Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kuke#NASDAQ">KUKE</a>) jumped 27% to $2.7650.</li>
<li>HUB Cyber Security Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hubc#NASDAQ">HUBC</a>) gained 24% to $1.61 after gaining over 11% on Friday.</li>
<li>Edgio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/egio#NASDAQ">EGIO</a>) gained 24% to $22.18.</li>
<li>Kaival Brands Innovations Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kavl#NASDAQ">KAVL</a>) surged 23.6% to $3.30.</li>
<li>Envoy Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/coch#NASDAQ">COCH</a>) gained 22.6% to $6.19.</li>
<li>Medical Properties Trust, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mpw#NYSE">MPW</a>) rose 19.9% to $4.7850 after the company announced that it sold its majority interest in Utah Hospitals.</li>
<li>CareMax, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cmax#NASDAQ">CMAX</a>) climbed 19.5% to $3.78.</li>
<li>SES AI Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ses#NYSE">SES</a>) surged 18.7% to $1.77.</li>
<li>Mobile-health Network Solutions (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mndr#NASDAQ">MNDR</a>) gained 17.7% to $17.67.</li>
<li>Adial Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adil#NASDAQ">ADIL</a>) rose 16.7% to $2.72.</li>
<li>ProKidney Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prok#NASDAQ">PROK</a>) gained 16.7% to $2.0426.</li>
<li>Biotricity, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/btcy#NASDAQ">BTCY</a>) rose 16.5% to $1.34.</li>
<li>Yatsen Holding Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ysg#NYSE">YSG</a>) gained 13.3% to $3.41.</li>
<li>Destiny Tech100 Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dxyz#NASDAQ">DXYZ</a>) shares gained 12.8% to $32.71 after dipping 42% on Friday.</li>
<li>Encore Wire Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wire#NASDAQ">WIRE</a>) surged 11.7% to $291.60 after the company entered an agreement to be acquired by Prysmian for $290 per share in cash.</li>
<li>Century Aluminum Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cenx#NASDAQ">CENX</a>) gained 9.5% to $18.05.</li>
<li>Extreme Networks, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/extr#NASDAQ">EXTR</a>) gained 5.7% to $11.31. B. Riley Securities analyst Dave Kang upgraded Extreme Networks from Neutral to Buy and maintained a $14 price target.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Marinus Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrns#NASDAQ">MRNS</a>) shares dipped 77% to $1.6800 after the company provided an update on the Phase 3 RAISE trial and reported preliminary Q1 financial results.</li>
<li>Swvl Holdings Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/swvl#NASDAQ">SWVL</a>) fell 35% to $8.58.</li>
<li>VIA optronics AG (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/viao#NASDAQ">VIAO</a>) dipped 34% to $0.2765.</li>
<li>Veru Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/veru#NASDAQ">VERU</a>) fell 24% to $1.1550. Oppenheimer analyst Leland Gershell reiterated Veru with an Outperform and lowered the price target from $7 to $5.</li>
<li>Rent the Runway, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rent#NASDAQ">RENT</a>) dipped 19.8% to $15.42.</li>
<li>NextPlat Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxpl#NASDAQ">NXPL</a>) fell 19.8% to $1.50 after jumping 24% on Friday. The company entered into a definitive business combination agreement with its majority-owned subsidiary Progressive Care Inc.</li>
<li>Cyngn Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cyn#NASDAQ">CYN</a>) shares fell 19.1% to $0.1170 after declining around 7% on Friday.</li>
<li>ProMIS Neurosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pmn#NASDAQ">PMN</a>) fell 15.6% to $1.95.</li>
<li>Biohaven Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bhvn#NASDAQ">BHVN</a>) dipped 15.4% to $44.90. Biohaven showcased innovative neuroscience portfolio with 20 presentations at the 2024 AAN Annual Meeting.</li>
<li>Neumora Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nmra#NASDAQ">NMRA</a>) shares declined 15.1% to $11.48 after the FDA placed a clinical hold on the company&#39;s Phase 1 NMRA-266 study.</li>
<li>Alterity Therapeutics Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/athe#NASDAQ">ATHE</a>) dipped 15% to $2.49.</li>
<li>Surf Air Mobility Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/srfm#NASDAQ">SRFM</a>) fell 15% to $0.53.</li>
<li>IM Cannabis Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/imcc#NASDAQ">IMCC</a>) fell 14.2% to $0.5399.</li>
<li>Polestar Automotive Holding Uk Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/psny#NASDAQ">PSNY</a>) fell 12.7% to $1.2699. On Friday, Cantor Fitzgerald analyst Andres Sheppard reiterated Polestar Automotive with an Overweight and maintained a $5 price target.</li>
<li>Desktop Metal, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dm#NYSE">DM</a>) fell 10.8% to $0.8510.</li>
<li>Local Bounti Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/locl#NYSE">LOCL</a>) declined 10.2% to $2.1550.</li>
<li>Q32 Bio Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qttb#NASDAQ">QTTB</a>) fell 10% to $26.00.</li>
<li>SunPower Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/spwr#NASDAQ">SPWR</a>) fell 8.3% to $2.2750.</li>
<li>Informatica Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/infa#NASDAQ">INFA</a>) dipped 8.1% to $35.36 amid increased volatility following reports suggesting Salesforce is in talks to buy the company.</li>
<li>TRACON Pharmaceuticals Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcon#NASDAQ">TCON</a>) declined 8.1% to $2.1699 after falling around 9% on Friday.</li>
<li>NOVONIX Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nvx#NYSE">NVX</a>) declined 7.2% to $2.63.</li>
<li>AudioEye, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aeye#NASDAQ">AEYE</a>) fell 6.6% to $12.86 after declining around 7% on Friday.</li>
<li>OncoCyte Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocx#NASDAQ">OCX</a>) fell 6.6% to $2.5301. Oncocyte announced a transplant assay partnership agreement with Bio-Rad laboratories.</li>
<li>BlackBerry Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bb#NYSE">BB</a>) fell 6.1% to $2.8650.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/04/38249138/dow-jumps-over-300-points-goldman-sachs-posts-upbeat-earnings"> Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings</a>

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Monday.
The Dow traded up 0.35% to 38,114.61 while the NASDAQ rose 0.07% to 16,187.02. The S&amp;P 500 also rose, gaining, 0.26% to 5,136.94.
Check This Out: <a href="https://www.benzinga.com/news/24/04/38218786/best-buy-box-and-2-other-stocks-insiders-are-selling"> Best Buy, Box And 2 Other Stocks Insiders Are Selling </a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Health care shares jumped by 0.7% on Friday.
In trading on Friday, real estate shares fell by 1.1%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
Charles Schwab Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/schw#NYSE">SCHW</a>) reported better-than-expected first-quarter earnings on Monday.
Charles Schwab reported a first-quarter 2024 adjusted net income decline of 17% Y/Y to $1.469 billion. Adjusted EPS fell 20% Y/Y to 74 cents, which came in line with the consensus. Revenue fell 7% to $4.74 billion, marginally beating the consensus of $4.71 billion.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Soligenix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sngx#NASDAQ">SNGX</a>) shares shot up 49% to $0.5802 after the company announced that it was granted orphan drug designation to the active ingredient in MarVax for the prevention and post-exposure prophylaxis against MARV infection by the FDA.
Shares of Longeveron Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lgvn#NASDAQ">LGVN</a>) got a boost, surging 52% to $2.5650 following insider buys from multiple company executives.
Snap One Holdings Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snpo#NASDAQ">SNPO</a>) shares were also up, gaining 30% to $10.61 after the company announced that it will be acquired by Resideo Technologies.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Marinus Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrns#NASDAQ">MRNS</a>) shares dropped 79% to $1.5792 after the company provided an update on the Phase 3 RAISE trial and reported preliminary first-quarter financial results.
Shares of Neumora Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nmra#NASDAQ">NMRA</a>) were down 14% to $11.67 after the FDA placed a clinical hold on the company&#39;s Phase 1 NMRA-266 study.
Ultragenyx Pharmaceutical Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rare#NASDAQ">RARE</a>) was down, falling 10% to $42.46 after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.
Also Check This Out:<a href="https://www.benzinga.com/news/24/04/38246593/wall-streets-most-accurate-analysts-views-on-3-tech-stocks-with-over-4-dividend-yields"> Wall Street&#39;s Most Accurate Analysts&#39; Views On 3 Tech Stocks With Over 4% Dividend Yields </a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded down 1.3% to $84.55 while gold traded down 0.5% at $2,362.00.
Silver traded up 0.8% to $28.55 on Friday, while copper rose 1.7% to $4.3315.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were mostly higher today. The eurozone&rsquo;s STOXX 600 rose 0.06%, London&rsquo;s FTSE 100 fell 0.48% while Spain&rsquo;s IBEX 35 Index fell 0.11% The German DAX gained 0.39% French CAC 40 climbed 0.31% while Italy&rsquo;s FTSE MIB Index jumped 0.45%.
Industrial production in the eurozone increased by 0.8% month-over-month in February.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed mostly lower on Monday, with Japan&rsquo;s Nikkei 225 falling 0.74%, Hong Kong&rsquo;s Hang Seng Index dropping 0.72%, China&rsquo;s Shanghai Composite gaining 1.26% and India&rsquo;s S&amp;P BSE Sensex dipping 1.14%.
Indian merchandise trade deficit shrank to $15.6 billion in March versus a year-ago gap of $18.1 billion, while wholesale prices rose by 0.53% year-over-year in March versus a 0.20% gain in the prior month.
&nbsp;
<h3>Economics</h3>
&nbsp;
The NY Empire State Manufacturing Index climbed to -14.3 in April versus prior month&rsquo;s reading of -20.9.
Retail sales increased 0.7% month-over-month in March following a revised 0.9% rise in February.
The NAHB/Wells Fargo Housing Market Index in came in unchanged at 51.0 in April.
Total business inventories increased by 0.4% month-over-month in February, versus market expectations of a 0.3% rise.
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38248683/bitcoin-surpasses-66-000-core-emerges-as-top-gainer"> Bitcoin Surpasses $66,000; Core Emerges As Top Gainer </a>

Monday,&nbsp;Ultragenyx Pharmaceutical Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/g38244767/ultragenyx-announces-positive-interim-phase-12-data-in-patients-with-angelman-syndrome-after-treat" rel="noreferrer noopener">and nerve-related symptoms</a>.
Patients in Expansion Cohorts A &amp; B treated with a set dose and regimen of GTX-102 showed rapid and clinically meaningful improvement across multiple domains consistent with or exceeding Dose-escalation Cohorts 4-7 data at Day 170.&nbsp;
Treatment of the dose-escalation cohorts 4-7 showed long-term increasing and sustained clinical benefits far exceeding Natural History data at Day 758.&nbsp;
Expansion Cohorts at Day 170 on 24 patients:
<ul>
<li>Cognition and receptive communication showed rapid and clinically significant improvement compared with Natural History data.&nbsp;</li>
<li>&nbsp;Hyperactivity and noncompliance showed rapid and clinically significant improvement at Day 170 compared with Natural History data.</li>
<li>&nbsp;Sleep, gross motor function, and behavior assessed by ASA showed rapid and clinically meaningful improvement, exceeding treatment benefit observed in the Dose-escalation Cohorts at Day 170.</li>
<li>&nbsp;Multi-domain Responder Index (MDRI) analysis across the four domains of Cognition, Receptive Communication, Behavior and Sleep resulted in a total net response of +2.0 (p-value &lt;0.0001). Most patients had already achieved a total net response of +2 to +4 domains, demonstrating improvement exceeding the minimally important difference threshold in several domains even at this early Day 170 timepoint.</li>
</ul>
Dose-escalation Cohorts up to Day 758:
<ul>
<li>Cognition showed continuing long-term improvement compared with Natural History data and exceeded the threshold of clinical significance by many-fold in many patients.</li>
<li>&nbsp;Behavior and sleep assessed by ASA showed continuing clinically meaningful improvement.</li>
<li>&nbsp;Receptive communication measured by Bayley-4 showed sustained and clinically significant improvement compared with Natural History data.</li>
<li>&nbsp;Gross motor function assessed by Bayley-4 showed continued and clinically significant improvement compared with previously reported Natural History data.</li>
<li>&nbsp;MDRI analysis across the four domains of cognition, receptive communication, behavior, and sleep resulted in a total net response of +2.0 on Day 338. The majority of patients had a total net response of +2 to +4 and a 2- to 5-fold improvement over the MID threshold in several domains.</li>
</ul>
There were no unexpected serious adverse events. Three patients had serious adverse events (mild to moderate) of lower extremity weakness assessed as related to study treatment &#8211; one in Cohort 7, two in Cohorts A &amp; B; none reported in Cohorts C–E to date.&nbsp;
All resolved rapidly without sequelae and remain in the study without ongoing safety concerns.
Price Action:&nbsp;RARE shares are down 9.55% at $42.51 on the last check Monday.

Health Care

$RARE

Rare Disease-Focused-Ultragenyx Pharmaceutical Stock Falls On Serious Adverse Events In Eaarly Genetic Disorder Study

Ultragenyx shares are trading lower after the company announced interim Phase 1/2 data in patients with Angelman Syndrome after treatment with GTX-102.

U.S. stock futures were higher this morning, with the Dow futures gaining over 200 points on Monday.
Shares of Marinus Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrns#NASDAQ">MRNS</a>) fell sharply in today&rsquo;s pre-market trading after the company issued an update on the Phase 3 RAISE Trial and reported preliminary first <a href="https://www.benzinga.com/quote/MRNS">quarter 2024 financial results</a>.
Marinus Pharma reported Prelim ZTALMY (Ganaxolone) net product revenue of $7.4 million to $7.6 million for the first quarter.
Marinus Pharmaceuticals shares dipped 74.2% to $1.94in pre-market trading.
Here are some big stocks recording losses in today&rsquo;s pre-market trading session.
<ul>
<li>Neumora Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nmra#NASDAQ">NMRA</a>) shares declined 17.1% to $11.25 pre-market trading after the FDA placed a clinical hold on the company&#39;s Phase 1 NMRA-266 study.</li>
<li>Roadzen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rdzn#NASDAQ">RDZN</a>) shares fell 14% to $5.04 in pre-market trading.</li>
<li>Ultragenyx Pharmaceutical Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rare#NASDAQ">RARE</a>) shares fell 11.4% to $41.64 in pre-market trading after the company disclosed interim Phase 1/2 data in patients with angelman syndrome after treatment with GTX-102.</li>
<li>Cogent Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cogt#NASDAQ">COGT</a>) shares declined 7.7% to $6.01 in pre-market trading. Cogent Biosciences recently reported preclinical data from CNS-Penetrant ErbB2 Inhibitor Program.</li>
<li>Polestar Automotive Holding UK PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/psny#NASDAQ">PSNY</a>) shares fell 7.2% to $1.35 in pre-market trading.</li>
<li>Molina Healthcare, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/moh#NYSE">MOH</a>) shares fell 7.1% to $350.00 in pre-market trading.</li>
<li>TORM plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trmd#NASDAQ">TRMD</a>) shares slipped 3.1% to $32.92 in pre-market trading.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38244618/top-3-tech-stocks-that-may-explode-this-month"> Top 3 Tech Stocks That May Explode This Month</a>
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>

Pre-Market Outlook

COGT

RDZN

TRMD

Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Patients in Expansion Cohorts A &amp; B treated with a set dose and regimen of GTX-102 showed rapid and clinically meaningful improvement across multiple domains consistent with or exceeding Dose-escalation Cohorts 4-7 data at Day 170. Treatment of the Dose-escalation Cohorts 4-7 showed long-term increasing and sustained clinical benefit far exceeding Natural History data at Day 758.

Ultragenyx Reveal New Data From Phase 1/2 Study Of GTX-102 For Treatment Of Angelman Syndrome

Conference call now scheduled for Monday, April 15 at 8:00 a.m. ET &nbsp;
Updated registration link below
NOVATO, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) today announced that the conference call to discuss new clinical efficacy and safety data from the Phase 1/2 study of GTX-102 for the treatment of Angelman syndrome that will be presented at the American Academy of Neurology Meeting (AAN), will now be taking place on Monday, April 15, 2024 at 8 a.m. Eastern Time (ET). The slides accompanying the call will be shared on company's website at <a href="https://www.globenewswire.com/Tracker?data=Df3ed1fUU26v-D6MDVxwO83Ha683C0Unmd9n94pOvc6KcGmY8P-sSrNfRhcWx9KFypgRYHneqxvOcGiIznMCUTC5D9xGS2P2nrRD7-RY98fJcsAnFMdfXy2XzViWVrabBTIMKYA11xMOrrwV49qJL10H5cWyKZt2E2mNmDiXLYY=">https://ir.ultragenyx.com/events-presentations</a> before the call.
Conference Call and Webcast Information
The live and replayed webcast of the call will be available through the company's website at <a href="https://www.globenewswire.com/Tracker?data=Df3ed1fUU26v-D6MDVxwO83Ha683C0Unmd9n94pOvc6KcGmY8P-sSrNfRhcWx9KF5Ma5C1qkWkgO2jei-gBwA3cji22DaorXNaAakccft0CrRJ3BdcwzJCxQvcSXWRex7pGFJa4geIPd1zz7vqo0J4U7PIgcAEqatx6XuW5oSEc=">https://ir.ultragenyx.com/events-presentations</a>.

Events

Ultragenyx Announces Update To Conference Call Timing To Discuss New Data From GTX-102 In Patients With Angelman Syndrome; Conference Call Now Scheduled For Monday, April 15 At 8:00 a.m. ET

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ultragenyx Pharmaceutical (RARE – Research Report) a...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Neurocrine (NBIX – Research Report) and Ultragenyx Pharmaceutical...

Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Ultragenyx Pharmaceutical (RARE)

In a report released today, Tiago Fauth from Wells Fargo maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report), with a pric...

Ultragenyx Pharmaceutical: Strong Buy Rating on Growth Prospects and Pipeline Potential

Ultragenyx Pharmaceutical GAAP EPS of -$2.03 misses by $0.28, revenue of $108.8M misses by $7.64M

Ultragenyx Pharmaceutical, Inc. (RARE) Q1 2024 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Ultragenyx Pharmaceutical (NASDAQ:<a href="https://investorplace.com/stock-quotes/rare-stock-quote/">RARE</a>) just reported results for the first quarter of 2024.<ul><li>Ultragenyx Pharmaceutical reported earnings per share of -$2.03. This was below the analyst estimate for EPS of -$1.76.</li><li>The company reported revenue of $108.83 million.</li><li>This was 6.32% worse than the analyst estimate for revenue of $116.17 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/rare-stock-earnings-ultragenyx-pharmaceutical-for-q1-of-2024/">RARE Stock Earnings: Ultragenyx Pharmaceutical Misses EPS, Misses Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

RARE Stock Earnings: Ultragenyx Pharmaceutical Misses EPS, Misses Revenue for Q1 2024

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ultragenyx Pharmaceutical (RARE – Research Report), ...

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Amgen (AMGN) and Zimmer Biomet Holdings (ZBH)

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Cigna (CI) and Genmab (GMAB)

Wedbush analyst Laura Chico maintained a Hold rating on Ultragenyx Pharmaceutical (RARE – Research Report) today and set a price target of $47.00. ...

Wedbush Reaffirms Their Hold Rating on Ultragenyx Pharmaceutical (RARE)

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report) today. The company's ...

Bank of America Securities Sticks to Its Buy Rating for Ultragenyx Pharmaceutical (RARE)

AMGN

GMAB

KRYS

NBIX

Press Releases

Ultragenyx to Participate at Investor Conferences in March

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting

Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome

Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102

Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update

Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Ultragenyx Pharmaceutical Stock (NASDAQ:RARE), Short Interest Report

People Also Watch